O	0	4	Long
O	4	5	-
O	5	9	term
O	10	17	results
O	18	20	of
B-intervention	21	37	hypofractionated
I-intervention	38	47	radiation
I-intervention	48	55	therapy
O	56	59	for
O	60	66	breast
O	67	73	cancer
O	73	74	.

O	75	78	The
O	79	86	optimal
O	87	100	fractionation
O	101	109	schedule
O	110	113	for
O	114	119	whole
O	119	120	-
O	120	126	breast
O	127	138	irradiation
O	139	144	after
O	145	151	breast
O	151	152	-
O	152	162	conserving
O	163	170	surgery
O	171	173	is
O	174	181	unknown
O	181	182	.

O	183	185	We
O	186	195	conducted
O	196	197	a
O	198	203	study
O	204	206	to
O	207	216	determine
O	217	224	whether
O	225	226	a
O	227	243	hypofractionated
O	244	245	3
O	245	246	-
O	246	250	week
O	251	259	schedule
O	260	262	of
O	263	268	whole
O	268	269	-
O	269	275	breast
O	276	287	irradiation
O	288	290	is
O	291	293	as
O	294	303	effective
O	304	306	as
O	307	308	a
O	309	310	5
O	310	311	-
O	311	315	week
O	316	324	schedule
O	324	325	.

B-eligibility	326	331	Women
I-eligibility	332	336	with
I-eligibility	337	345	invasive
I-eligibility	346	352	breast
I-eligibility	353	359	cancer
I-eligibility	360	363	who
I-eligibility	364	367	had
I-eligibility	368	377	undergone
I-eligibility	378	384	breast
I-eligibility	384	385	-
I-eligibility	385	395	conserving
I-eligibility	396	403	surgery
I-eligibility	404	407	and
I-eligibility	408	410	in
I-eligibility	411	415	whom
I-eligibility	416	425	resection
I-eligibility	426	433	margins
I-eligibility	434	438	were
I-eligibility	439	444	clear
I-eligibility	445	448	and
I-eligibility	449	457	axillary
I-eligibility	458	463	lymph
I-eligibility	464	469	nodes
I-eligibility	470	474	were
I-eligibility	475	483	negative
O	484	488	were
O	489	497	randomly
O	498	506	assigned
O	507	509	to
O	510	517	receive
O	518	523	whole
O	523	524	-
O	524	530	breast
O	531	542	irradiation
O	543	549	either
O	550	552	at
O	553	554	a
B-control	555	563	standard
I-control	564	568	dose
O	569	571	of
O	572	574	50
O	574	575	.
O	575	576	0
O	577	579	Gy
O	580	582	in
O	583	585	25
O	586	595	fractions
O	596	600	over
O	601	602	a
O	603	609	period
O	610	612	of
O	613	615	35
O	616	620	days
O	621	622	(
O	622	625	the
O	626	633	control
O	634	639	group
O	639	640	)
O	641	643	or
O	644	646	at
O	647	648	a
O	649	653	dose
O	654	656	of
O	657	659	42
O	659	660	.
O	660	661	5
O	662	664	Gy
O	665	667	in
O	668	670	16
O	671	680	fractions
O	681	685	over
O	686	687	a
O	688	694	period
O	695	697	of
O	698	700	22
O	701	705	days
O	706	707	(
O	707	710	the
O	711	727	hypofractionated
O	727	728	-
O	728	737	radiation
O	738	743	group
O	743	744	)
O	744	745	.

O	746	749	The
B-outcome	750	754	risk
I-outcome	755	757	of
I-outcome	758	763	local
I-outcome	764	774	recurrence
I-outcome	775	777	at
I-outcome	778	780	10
I-outcome	781	786	years
O	787	790	was
B-cv-bin-percent	791	792	6
I-cv-bin-percent	792	793	.
I-cv-bin-percent	793	794	7
I-cv-bin-percent	794	795	%
O	796	801	among
O	802	805	the
B-control-participants	806	809	612
O	810	815	women
O	816	824	assigned
O	825	827	to
O	828	836	standard
O	837	848	irradiation
O	849	851	as
O	852	860	compared
O	861	865	with
B-iv-bin-percent	866	867	6
I-iv-bin-percent	867	868	.
I-iv-bin-percent	868	869	2
I-iv-bin-percent	869	870	%
O	871	876	among
O	877	880	the
B-intervention-participants	881	884	622
O	885	890	women
O	891	899	assigned
O	900	902	to
O	903	906	the
O	907	923	hypofractionated
O	924	931	regimen
O	932	933	(
O	933	941	absolute
O	942	952	difference
O	952	953	,
O	954	955	0
O	955	956	.
O	956	957	5
O	958	968	percentage
O	969	975	points
O	975	976	;
O	977	979	95
O	979	980	%
O	981	991	confidence
O	992	1000	interval
O	1001	1002	[
O	1002	1004	CI
O	1004	1005	]
O	1005	1006	,
O	1007	1008	-
O	1008	1009	2
O	1009	1010	.
O	1010	1011	5
O	1012	1014	to
O	1015	1016	3
O	1016	1017	.
O	1017	1018	5
O	1018	1019	)
O	1019	1020	.

B-outcome	1021	1023	At
I-outcome	1024	1026	10
I-outcome	1027	1032	years
O	1032	1033	,
B-cv-bin-percent	1034	1036	71
I-cv-bin-percent	1036	1037	.
I-cv-bin-percent	1037	1038	3
I-cv-bin-percent	1038	1039	%
O	1040	1042	of
O	1043	1048	women
O	1049	1051	in
O	1052	1055	the
O	1056	1063	control
O	1064	1069	group
O	1070	1072	as
O	1073	1081	compared
O	1082	1086	with
B-iv-bin-percent	1087	1089	69
I-iv-bin-percent	1089	1090	.
I-iv-bin-percent	1090	1091	8
I-iv-bin-percent	1091	1092	%
O	1093	1095	of
O	1096	1099	the
O	1100	1105	women
O	1106	1108	in
O	1109	1112	the
O	1113	1129	hypofractionated
O	1129	1130	-
O	1130	1139	radiation
O	1140	1145	group
O	1146	1149	had
O	1150	1151	a
B-outcome	1152	1156	good
I-outcome	1157	1159	or
I-outcome	1160	1169	excellent
I-outcome	1170	1178	cosmetic
I-outcome	1179	1186	outcome
O	1187	1188	(
O	1188	1196	absolute
O	1197	1207	difference
O	1207	1208	,
O	1209	1210	1
O	1210	1211	.
O	1211	1212	5
O	1213	1223	percentage
O	1224	1230	points
O	1230	1231	;
O	1232	1234	95
O	1234	1235	%
O	1236	1238	CI
O	1238	1239	,
O	1240	1241	-
O	1241	1242	6
O	1242	1243	.
O	1243	1244	9
O	1245	1247	to
O	1248	1249	9
O	1249	1250	.
O	1250	1251	8
O	1251	1252	)
O	1252	1253	.

O	1254	1257	Ten
O	1258	1263	years
O	1264	1269	after
O	1270	1279	treatment
O	1279	1280	,
O	1281	1292	accelerated
O	1292	1293	,
O	1294	1310	hypofractionated
O	1311	1316	whole
O	1316	1317	-
O	1317	1323	breast
O	1324	1335	irradiation
O	1336	1339	was
O	1340	1343	not
O	1344	1352	inferior
O	1353	1355	to
O	1356	1364	standard
O	1365	1374	radiation
O	1375	1384	treatment
O	1385	1387	in
O	1388	1393	women
O	1394	1397	who
O	1398	1401	had
O	1402	1411	undergone
O	1412	1418	breast
O	1418	1419	-
O	1419	1429	conserving
O	1430	1437	surgery
O	1438	1441	for
O	1442	1450	invasive
O	1451	1457	breast
O	1458	1464	cancer
O	1465	1469	with
O	1470	1475	clear
O	1476	1484	surgical
O	1485	1492	margins
O	1493	1496	and
O	1497	1505	negative
O	1506	1514	axillary
O	1515	1520	nodes
O	1520	1521	.

O	1522	1523	(
O	1523	1537	ClinicalTrials
O	1537	1538	.
O	1539	1542	gov
O	1543	1549	number
O	1549	1550	,
O	1551	1562	NCT00156052
O	1562	1563	.
O	1563	1564	)
